Suppr超能文献

在能力验证和桥接研究背景下,干扰素-γ酶联免疫斑点试验的变异性

Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies.

作者信息

Rountree Wes, Berrong Mark, Sanchez Ana M, Denny Thomas N, Ferrari Guido

机构信息

Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

出版信息

J Immunol Methods. 2016 Jun;433:69-76. doi: 10.1016/j.jim.2016.03.004. Epub 2016 Mar 25.

Abstract

Assays that assess cellular mediated immune responses performed under Good Clinical Laboratory Practice (GCLP) guidelines are required to provide specific and reproducible results. Defined validation procedures are required to establish the Standard Operating Procedure (SOP), include pass and fail criteria, as well as implement positivity criteria. However, little to no guidance is provided on how to perform longitudinal assessment of the key reagents utilized in the assay. Through the External Quality Assurance Program Oversight Laboratory (EQAPOL), an Interferon-gamma (IFN-γ) Enzyme-linked immunosorbent spot (ELISpot) assay proficiency testing program is administered. A limit of acceptable within site variability was estimated after six rounds of proficiency testing (PT). Previously, a PT send-out specific within site variability limit was calculated based on the dispersion (variance/mean) of the nine replicate wells of data. Now an overall 'dispersion limit' for the ELISpot PT program within site variability has been calculated as a dispersion of 3.3. The utility of this metric was assessed using a control sample to calculate the within (precision) and between (accuracy) experiment variability to determine if the dispersion limit could be applied to bridging studies (studies that assess lot-to-lot variations of key reagents) for comparing the accuracy of results with new lots to results with old lots. Finally, simulations were conducted to explore how this dispersion limit could provide guidance in the number of replicate wells needed for within and between experiment variability and the appropriate donor reactivity (number of antigen-specific cells) to be used for the evaluation of new reagents. Our bridging study simulations indicate using a minimum of six replicate wells of a control donor sample with reactivity of at least 150 spot forming cells per well is optimal. To determine significant lot-to-lot variations use the 3.3 dispersion limit for between and within experiment variability.

摘要

按照良好临床实验室规范(GCLP)指南进行的评估细胞介导免疫反应的检测,需要提供特异且可重复的结果。需要定义验证程序来建立标准操作规程(SOP),包括通过和失败标准,以及实施阳性标准。然而,对于如何对检测中使用的关键试剂进行纵向评估,几乎没有提供指导。通过外部质量保证计划监督实验室(EQAPOL),实施了一项干扰素-γ(IFN-γ)酶联免疫斑点(ELISpot)检测能力验证计划。在六轮能力验证(PT)后估计了位点内可接受变异的限度。此前,根据数据的九个重复孔的离散度(方差/均值)计算了PT发送样本特有的位点内变异限度。现在,ELISpot PT计划位点内变异的总体“离散度限度”已计算为3.3。使用对照样本评估该指标的效用,以计算实验内(精密度)和实验间(准确度)变异,以确定离散度限度是否可应用于桥接研究(评估关键试剂批次间差异的研究),用于比较新批次与旧批次结果的准确性。最后,进行模拟以探索该离散度限度如何为实验内和实验间变异所需的重复孔数量以及用于评估新试剂的合适供体反应性(抗原特异性细胞数量)提供指导。我们的桥接研究模拟表明,使用至少六个重复孔的对照供体样本,每孔反应性至少为150个斑点形成细胞是最佳的。为了确定显著的批次间差异,使用3.3的离散度限度来评估实验间和实验内变异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a6c/4860083/5e74131d1f6d/nihms-774881-f0001.jpg

相似文献

本文引用的文献

5
Response definition criteria for ELISPOT assays revisited.ELISPOT 检测反应定义标准的再探讨。
Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验